|
1
|
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2010
|
5.62
|
|
2
|
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
|
J Clin Oncol
|
2009
|
3.69
|
|
3
|
Urgent need for a new staging system in advanced colorectal cancer.
|
J Clin Oncol
|
2008
|
1.39
|
|
4
|
Current opinion on optimal treatment for colorectal cancer.
|
Expert Rev Anticancer Ther
|
2013
|
0.96
|
|
5
|
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
|
Clin Colorectal Cancer
|
2005
|
0.93
|
|
6
|
Second-line therapy for advanced colorectal cancer.
|
Gastrointest Cancer Res
|
2007
|
0.90
|
|
7
|
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.
|
Eur J Cancer
|
2010
|
0.87
|
|
8
|
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
|
Clin Colorectal Cancer
|
2013
|
0.86
|
|
9
|
Vatalanib in advanced colorectal cancer: two studies with identical results.
|
J Clin Oncol
|
2011
|
0.85
|
|
10
|
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008.
|
Clin Colorectal Cancer
|
2010
|
0.80
|
|
11
|
Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001).
|
Lung Cancer
|
2004
|
0.79
|
|
12
|
Scheduling of fluorouracil: a forget-me-not in the jungle of doublets.
|
J Clin Oncol
|
2003
|
0.75
|